213 related articles for article (PubMed ID: 20213540)
1. Cholesterol in Alzheimer's disease and other amyloidogenic disorders.
Harris JR; Milton NG
Subcell Biochem; 2010; 51():47-75. PubMed ID: 20213540
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol and Alzheimer's disease--is there a relation?
Sjögren M; Mielke M; Gustafson D; Zandi P; Skoog I
Mech Ageing Dev; 2006 Feb; 127(2):138-47. PubMed ID: 16332384
[TBL] [Abstract][Full Text] [Related]
3. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
4. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
5. Role of amyloid precursor protein, amyloid-beta and gamma-secretase in cholesterol maintenance.
Hartmann T
Neurodegener Dis; 2006; 3(4-5):305-11. PubMed ID: 17047372
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease: the cholesterol connection.
Puglielli L; Tanzi RE; Kovacs DM
Nat Neurosci; 2003 Apr; 6(4):345-51. PubMed ID: 12658281
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol homeostasis and the pathophysiology of Alzheimer's disease.
Blain JF; Poirier J
Expert Rev Neurother; 2004 Sep; 4(5):823-9. PubMed ID: 15853509
[TBL] [Abstract][Full Text] [Related]
8. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model.
Kurinami H; Sato N; Shinohara M; Takeuchi D; Takeda S; Shimamura M; Ogihara T; Morishita R
Int J Mol Med; 2008 May; 21(5):531-7. PubMed ID: 18425343
[TBL] [Abstract][Full Text] [Related]
9. Brain cholesterol, statins and Alzheimer's Disease.
Kirsch C; Eckert GP; Koudinov AR; Müller WE
Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S113-9. PubMed ID: 14574624
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease. Bad for the heart, bad for the mind?
Marx J
Science; 2001 Oct; 294(5542):508-9. PubMed ID: 11641483
[No Abstract] [Full Text] [Related]
11. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Refolo LM; Pappolla MA; LaFrancois J; Malester B; Schmidt SD; Thomas-Bryant T; Tint GS; Wang R; Mercken M; Petanceska SS; Duff KE
Neurobiol Dis; 2001 Oct; 8(5):890-9. PubMed ID: 11592856
[TBL] [Abstract][Full Text] [Related]
12. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies.
Sorrentino G; Bonavita V
Neurol Sci; 2007 Apr; 28(2):63-71. PubMed ID: 17464468
[TBL] [Abstract][Full Text] [Related]
13. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide.
Puglielli L; Konopka G; Pack-Chung E; Ingano LA; Berezovska O; Hyman BT; Chang TY; Tanzi RE; Kovacs DM
Nat Cell Biol; 2001 Oct; 3(10):905-12. PubMed ID: 11584272
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol and statins in Alzheimer's disease: current controversies.
Fonseca AC; Resende R; Oliveira CR; Pereira CM
Exp Neurol; 2010 Jun; 223(2):282-93. PubMed ID: 19782682
[TBL] [Abstract][Full Text] [Related]
15. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
17. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?
Michikawa M
J Neurosci Res; 2003 Apr; 72(2):141-6. PubMed ID: 12671988
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
19. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
Hardy J; Selkoe DJ
Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
[TBL] [Abstract][Full Text] [Related]
20. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease.
Sahlin C; Pettersson FE; Nilsson LN; Lannfelt L; Johansson AS
Eur J Neurosci; 2007 Aug; 26(4):882-9. PubMed ID: 17714184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
